Association between lifelong classical psychedelics use and cardiovascular metabolic diseases

Simonsson, O., Osika, W., Carhart-Harris, R. etal. Lifetime classical psychedelics use and its association with cardiovascular metabolic disease. SCI Rep 11, 14427 (2021). https://doi.org/10.1038/s41598-021-93787-4

Commentary

The purpose of this study was to investigate the association between lifetime classical psychedelics use and cardiovascular metabolic disease.

Using data from the National Survey on Drug Use and Health (2005-2014), we examined the association between lifetime classic psychedelics use and two cardiovascular diseases: heart disease and diabetes.

Respondents who reported having tried classical psychedelics at least once in their lifetime had lower odds of heart disease and lower odds of diabetes in the past year.

These results suggest that the use of classical psychedelics may be beneficial to cardiometabolic health, and